These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6410534)

  • 21. In vivo interactions of autoantibodies to factor VIII with the factor VIII complex.
    Allain JP; Croissant MP; Lerolle D; Houbouyan L; Zuzel M; Frommel D
    Thromb Haemost; 1982 Oct; 48(2):142-5. PubMed ID: 6817443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of factors affecting the stability of frozen heparinized plasma.
    Palmer DS; Rosborough D; Perkins H; Bolton T; Rock G; Ganz PR
    Vox Sang; 1993; 65(4):258-70. PubMed ID: 8310678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved yields of factor VIII from heparinized plasma.
    Rock GA; Cruickshank WH; Tackaberry ES; Palmer DS
    Vox Sang; 1979; 36(5):294-300. PubMed ID: 462918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time course of changes in in vitro platelet function and plasma von willebrand factor activity (VIIIR:WF) and factor VIII-related antigen (VIIIR:Ag) in the diabetic rat.
    Winocour PD; Lopes-Virella M; Laimins M; Colwell JA
    J Lab Clin Med; 1983 Nov; 102(5):795-804. PubMed ID: 6415193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices.
    Manco-Johnson MJ; Nuss R; Jacobson LJ
    J Lab Clin Med; 2000 Jul; 136(1):74-9. PubMed ID: 10882230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Complement activation in citrate plasma--inhibitory effect of anticoagulants on serum complement activation].
    Kobayashi E; Kitano E; Kondo H; Kitamura H
    Rinsho Byori; 1999 Feb; 47(2):160-4. PubMed ID: 10097633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dissociation of human factor VIII and recombination of the fragments VIII-C and VIII-AG].
    Tran TH; Bounameaux H; Marbet GA; Duckert F
    Schweiz Med Wochenschr; 1979 Jul; 109(28):1029-34. PubMed ID: 462170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A collaborative study to establish a Korean Standard for factor VIII:C concentrate.
    Kang HN; Kim SN; Lee SH; Hong SH
    Thromb Res; 2004; 113(3-4):261-7. PubMed ID: 15140591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction.
    O'Donnell J; Tuddenham EG; Manning R; Kemball-Cook G; Johnson D; Laffan M
    Thromb Haemost; 1997 May; 77(5):825-8. PubMed ID: 9184386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of EDTA on routine and specialized coagulation testing and an easy method to distinguish EDTA-treated from citrated plasma samples.
    Crist RA; Gibbs K; Rodgers GM; Smock KJ
    Lab Hematol; 2009; 15(4):45-8. PubMed ID: 19923105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of copper on the structure and function of factor VIII subunits: evidence for an auxiliary role for copper ions in cofactor activity.
    Sudhakar K; Fay PJ
    Biochemistry; 1998 May; 37(19):6874-82. PubMed ID: 9578574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneity of human factor VIII. III. Transitions between forms of factor VIII present in cryoprecipitate and in cryosupernatant plasma.
    Over J; Bouma BN; Sixma JJ; Bolhuis PA; Vlooswijk RA
    J Lab Clin Med; 1980 Mar; 95(3):323-34. PubMed ID: 7354239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standardization of Factor VIII-IV. Establishment of the 3rd International Standard for Factor VIII: C concentrate.
    Barrowcliffe TW; Curtis AD; Thomas DP
    Thromb Haemost; 1983 Oct; 50(3):697-702. PubMed ID: 6417819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved blood preservation with 0.5CPD erythro-sol. Coagulation factor VIII activity and erythrocyte quality after delayed separation of blood.
    Solheim BG; Bergerud UE; Kjeldsen-Kragh J; Brosstad F; Mollnes TE; Högman CF; Eriksson L; Schutz R
    Vox Sang; 1998; 74(3):168-75. PubMed ID: 9595644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature.
    Zürcher M; Sulzer I; Barizzi G; Lämmle B; Alberio L
    Thromb Haemost; 2008 Feb; 99(2):416-26. PubMed ID: 18278194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of plasma quality as raw material for factor VIII:C concentrates. Storage of whole blood and plasma and interindividual plasma levels of fibrinopeptide A.
    Carlebjörk G; Blombäck M; Akerblom O
    Vox Sang; 1983; 45(3):233-42. PubMed ID: 6414186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A simple plasma anticoagulant-exchange method to increase the recovery of factor VIII in therapeutic concentrates.
    Cumming AM; Wensley RT; Winkelman L; Lane RS
    Vox Sang; 1990; 58(4):264-9. PubMed ID: 2119086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accumulative effect of DDAVP and heparin in increasing plasma factor VIII levels.
    Rock G; Palmer DS
    Vox Sang; 1981; 41(1):56-60. PubMed ID: 6798759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of anticoagulant on the in vitro level and stability of factor VIII procoagulant activity.
    Cumming AM; Wensley RT; Power DM; Delamore IW
    Thromb Res; 1987 Apr; 46(2):391-5. PubMed ID: 3111005
    [No Abstract]   [Full Text] [Related]  

  • 40. A biological standard for measurement of blood coagulation Factor VIII activity.
    Bangham DR; Biggs R; Brozović M; Denson KW; Skegg JL
    Bull World Health Organ; 1971; 45(3):337-51. PubMed ID: 5316913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.